Gyre Therapeutics director granted 40,000 stock options

Gyre Therapeutics director Rodney L. Nussbaum received a new stock option grant for 40,000 shares of common stock.

Rhea-AI Filing Summary

Gyre Therapeutics director Rodney L. Nussbaum received a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $5.95 per share, gives him the right to buy Gyre Therapeutics stock at that price until June 10, 2036.

The award was reported as a compensation-related grant, not an open-market purchase or sale. The option will vest in 12 equal monthly installments through June 10, 2027, subject to his continued service with the company. After this grant, he holds options for 40,000 underlying shares directly.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Nussbaum Rodney L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. . This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Key Figures

Option grant size: 40,000 shares Exercise price: $5.95 per share Underlying shares: 40,000 shares +3 more

6 metrics

Option grant size 40,000 shares Stock Option (Right to Buy) granted on June 10, 2026

Exercise price $5.95 per share Conversion or exercise price of the option

Underlying shares 40,000 shares Underlying common stock for the option

Expiration date June 10, 2036 Option expiration date

Shares after transaction 40,000 options Total derivative shares following transaction

Vesting schedule 12 monthly installments Vesting through June 10, 2027, subject to continued service

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 5.9500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"which will vest in 12 equal monthly installments through June 10, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gyre Therapeutics (GYRE) director Rodney L. Nussbaum report on this Form 4?

Rodney L. Nussbaum reported receiving a stock option grant for 40,000 shares of Gyre Therapeutics common stock. The option is a compensation-related award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.

How many Gyre Therapeutics (GYRE) shares are covered by Nussbaum’s new option grant?

The new option grant covers 40,000 shares of Gyre Therapeutics common stock. These are underlying shares that Nussbaum may purchase in the future by exercising the option at the specified exercise price if the award becomes fully vested.

What is the exercise price of Rodney Nussbaum’s Gyre Therapeutics (GYRE) stock options?

The option has an exercise price of $5.95 per share for Gyre Therapeutics common stock. This means Nussbaum can buy up to 40,000 shares at $5.95, regardless of the market price, once the options vest and before they expire.

When do Rodney Nussbaum’s Gyre Therapeutics (GYRE) options vest and expire?

The 40,000-share option vests in 12 equal monthly installments through June 10, 2027. The option expires on June 10, 2036, giving Nussbaum a long window to exercise the vested portions if he chooses to do so.

Is Nussbaum’s Gyre Therapeutics (GYRE) Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant, not a purchase or sale, of a stock option covering 40,000 shares. It is coded as a grant, award, or other acquisition, meaning it is part of his compensation rather than an open-market trade in Gyre Therapeutics stock.

How many Gyre Therapeutics (GYRE) options does Nussbaum hold after this grant?

After this grant, Nussbaum holds stock options for 40,000 underlying shares of Gyre Therapeutics common stock directly. This reflects the total derivative position reported in this filing, tied to the newly awarded option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 06:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nussbaum Rodney L

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.95	06/10/2026		A		40,000		(1)	06/10/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. . This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Thomas Eastling, as attorney-in-fact for Rodney Nussbaum	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)